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ORIGINAL ARTICLE / ÖZGÜN ARAŞTIRMA 
The roles of urine interleukin-13, CD80, CD28, matrix metalloproteinase-2 and 
granzyme B in the pathogenesis of childhood minimal change nephrotic syndrome
İdrar interlökin-13, CD80, CD28, matriks metaloproteinaz-2 ve granzim B‘nin çocukluk çağı 
minimal değişim nefrotik sendrom patogenezindeki rolleri
Cengiz Zeybek1, Duygu Övünç Hacıhamdioğlu1, Süleyman Tolga Yavuz2, Aysel Pekel3, Cihangir Akgün4, Burcu Bulum5, 
Kaan Gülleroğlu6, Aslı Kantar6, Aslı Kavaz5, Uğur Muşabak7, Fatoş Yalçınkaya8, Esra Baskın9, Faysal Gök10
ABSTRACT
Objective: Minimal change disease (MCD) is the most com-
mon cause of nephrotic syndrome in childhood but its patho-
genesis remains poorly understood. A T-cell-derived factor 
or factors were initially alleged as contributing to the disease 
pathogenesis. However, podocyte CD80 expression is now a 
commonly discussed theory. The aim of this study was to in-
vestigate the pathogenesis of MCD by determining urine inter-
leukin-13, CD80, CD28, matrix metalloproteinase-2 (MMP-2), 
and granzyme B levels. 
Methods: Thirty patients and thirty healthy children were eval-
uated in this study. Six patients had biopsy proven MCD. The 
remaining patients were considered to have MCD because of 
their age at time of diagnosis; response to steroid treatment, 
absence of gross hematuria, hypocomplementemia or renal 
failure; and normal blood pressures in the active stage. The 
nephrotic-phase urine interleukin-13, CD80, CD28, MMP-2, 
and granzyme B levels of all patients were compared with the 
remission-stage urine levels of the same patients and control 
subjects. The urine samples were collected immediately before 
the application of immunosuppressive drugs or other treatment 
modalities.
Results: Significantly higher interleukin-13, CD80, CD28, and 
MMP-2 levels were observed in the relapse period compared 
with both the remission period and control subjects. There was 
a significant positive correlation between the active-stage urine 
interleukin-13 and CD80 levels (r=0.619, p<0.001). 
Conclusion: Interleukin-13, CD80, CD28, and MMP-2 seem to 
have roles in the pathogenesis of MCD and using inhibitors of 
these molecules in treatment of steroid and immunosuppres-
sive-resistant MCD cases can be thought. J Clin Exp Invest 
2014; 5 (3): 354-361
Key words: Minimal change disease, Interleukin-13, B7 pro-
teins, MMP-2, granzyme B
ÖZET
Amaç: Minimal değişiklik hastalığı çocuklarda nefrotik sendro-
mun en sık nedenidir ve patogenezi hala aydınlatılamamıştır. 
Başlangıçta T hücresi kaynaklı faktör ya da faktörlerin hastalı-
ğın patogenezinden sorumlu olduğu ileri sürülmüştür. Fakat gü-
nümüzde hastalığın patogenezinde podosit CD80 ekspresyonu 
ön plana çıkmıştır. Bizim bu çalışmada amacımız hastaların 
idrar interlökin-13, CD80, CD28, matriks metaloproteinaz-2 ve 
granzim b düzeylerine bakarak hastalığın patogenezini anla-
maya çalışmaktır. 
Yöntemler: Bu amaçla 30 hasta ve 30 sağlıklı çocuktan oluşan 
kontrol grubu ile çalıştık. 6 hastanın biyopsi sonucu minimal 
değişiklik hastalığı idi. Diğer hastalara hastalığın ilk aktif dö-
nemindeki başlangıç yaşı, steroid tedavisine verdikleri cevap, 
hastalığın tanısı sırasında gros hematüri, hipokomplementemi, 
renal yetmezlik ve hipertansiyon olmaması nedeniyle minimal 
değişiklik hastalığı tanısı konuldu. Hastaların aktif faz idrar in-
terlökin-13, CD80, CD28, matriks metaloproteinaz-2 ve gran-
zim  b  düzeyleri  aynı  hastaların  remisyon  dönemi  ve  kontrol 
grubu ile karşılaştırıldı. İmmünsüpresif ilaçlar ya da diğer tedavi 
modaliteleri başlamadan hemen önce idrar örnekleri alındı.
Bulgular: Hastalığın aktif döneminde remisyon ve kontrol gru-
buna göre istatistiksel olarak anlamlı idrar interlökin-13, CD80, 
CD28 ve MMP-2 yüksekliği saptadık. Nefrotik faz idrar interlö-
kin-13 düzeyleri ile CD80 düzeyleri arasında pozitif korelasyon 
mevcuttu (r=0,619, p<0,001). 
Sonuç: İnterlökin-13, CD80, CD28 ve MMP-2 moleküllerinin 
minimal değişim hastalığı patogenezinde rolleri olduğu görüldü. 
Steroide ve immünsüpresiflere dirençli minimal değişim hasta-
lığı tedavisinde bu moleküllerin inhibitörlerinin kullanılması dü-
şünülebilir. 
Anahtar kelimeler: Minimal değişiklik hastalığı, interlökin-13, 
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INTRODUCTION
Minimal change disease (MCD) is the most com-
mon cause of nephrotic syndrome in childhood. 
MCD is characterized by a rapid response to steroid 
treatment. Therefore, the term “MCD” is generally 
used as a synonym for steroid-sensitive nephrotic 
syndrome (SSNS). Idiopathic nephrotic syndrome 
(INS) is a term that includes all cases of SSNS and 
steroid- resistant nephrotic syndrome (SRNS) [1]. 
The hypothesis that MCD involves T-cell dys-
function was introduced by Shalhoub in 1974 [2]. 
Later, cyclosporine was shown to block interleukin 
(IL)-2 releases, which is a T-cell cytokine, intensify-
ing the suspicion that T cells play a role in the patho-
genesis of MCD [3]. Although how T cells increase 
glomerular permeability remains unknown there 
is some evidence that a factor or factors released 
from T cells initiate the disease [4, 5].
Although controversial, MCD is frequently seen 
in patients with atopy and allergy [6]. These allergic 
diseases typically involve a TH2 immunological re-
sponse. Thus, increased IgE levels, a characteristic 
TH2 pattern, have been seen in patients with MCD 
[7]. IL-13 is an important cytokine that is secreted 
from TH2 cells. The importance of IL-13 in the 
pathogenesis of allergic diseases has been demon-
strated previously [8]. IL-13 may also be important 
in the pathogenesis of MCD [9]. 
In animal studies, the CD80 molecule has been 
shown to be prominent in podocytes in pathological 
conditions such as lipopolysaccharide-induced pro-
teinuria [10]. Increased urinary excretion of CD80 
has been shown to be relatively specific for MCD 
[11]. In fact, it has been asserted that this molecule 
can be used to distinguish MCD (SSNS) and focal 
segmental glomerulosclerosis (SRNS) at the time of 
diagnosis [12]. 
The CD28 molecule is present on the surface 
of T cells and is responsible for T-cell activation [13]. 
The urinary level of the identical molecule CTLA-
4, which has an inhibitory effect and is expressed 
on the surface of T cells has been shown to be de-
creased during the active stage in with INS, albeit 
not significantly so [11]. However, the role of CD28 
in MCD has not been investigated. 
Matrix metalloproteinase-2 (MMP-2) destroys 
the type-IV collagen molecule, which is the major 
structural component of the basal membrane, and 
all MMPs destroy extracellular matrix proteins [14]. 
The type-IV collagen molecule is present in the 
glomerular basal membrane, and few studies have 
evaluated the role of MMP-2 in the pathogenesis of 
childhood INS. Moreover, most investigated patients 
were taking immunosuppressive drugs [15,16]. 
Granzyme B is present in cytotoxic T lympho-
cytes (CTLs) and natural killer (NK) cells. The most 
important function of granzyme B is to kill the target 
cell by stimulating apoptosis together with perforin 
[17]. Granzyme B is also present in T regulatory 
(Treg) cells, which are known to be dysfunctional in 
the active stage of MCD [18]. Granzyme B, which 
is present in Treg cells, increases the immunosup-
pressive effects of Treg cells, however, the relation-
ship between granzyme B and nephrotic syndrome 
is unknown [19, 20]. Furthermore, it has been shown 
that the numbers of zeta chains are decreased in 
NK cells in the active stage of INS [21]. 
In this study, we evaluated the urine IL-13, 
granzyme B, CD80, CD28 and MMP-2 levels in chil-
dren with MCD in both the active (nephrotic) and 
remission stages. The children were taking no im-
munosuppressives, including steroids. The levels of 
all parameters were compared among the children 
in the patient group as well as with a separate con-
trol group. Our aim was to at least partly elucidate 
the immunopathogenesis of this disease and thus 
identify potential new treatment modalities. 
METHODS
Patients and study design
Patients with SSNS, either newly diagnosed or in 
remission (for at least 2 months), were included in 
the study. Thirty patients were used in IL-13, CD80; 
CD28, MMP-2 and granzyme B studies. Three of 
30 patients were initial diagnosis of MCD and the 
other 27 patients were in relapse period while in re-
mission. Thirty healthy children of similar age and 
sex (no systemic or renal disease as determined by 
physical examination and laboratory studies) were 
evaluated in the control group of CD80 study, 19 
healthy children were evaluated in the control group 
of IL-13, CD28, granzyme B, and MMP-2 studies. 
Informed consent was obtained from the parents of 
all patients and control subjects.
Six patients had biopsy proven MCD. The re-
maining were considered to have MCD because of 
their age at the time of diagnosis; their response 
to steroid treatment; the absence of gross hematu-
ria, hypocomplementemia, or renal failure; and the 
presence of a normal blood pressure in the active 
stage of the disease.Zeybek C. et al. Urine IL-13, CD80, CD28, MMP-2 and granzyme B in childhood nephrotic syndrome 356
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Active stage urine IL-13, granzyme B, CD80, 
CD28, and MMP-2 levels of all patients were com-
pared with their levels during remission and those 
of the control group. No patients in either the ac-
tive stage or remission were taking any immuno-
suppressive (including steroids) or other treatments 
(angiotensin-converting inhibitors, etc.) at the time 
of urine sample collection. We recruited the same 
patients who not taking any medications at time of 
urine sample collection in order to obtain more reli-
able results. 
Relapse of MCD was not associated with infec-
tion according to clinical and laboratory examina-
tions. 
Nephrotic syndrome was diagnosed according 
to the outlined by the “International Study of Kidney 
Diseases in Children” [22]. 
The  patients’  glomerular  filtration  rates  were 
calculated according to the modified Schwartz for-
mula [23].
This study was approved by the Gülhane Mili-
tary Medical Academy Ethics Committee and per-
formed in compliance with the Declaration of Hel-
sinki.
Urine measurements
Five-milliliter  urine  samples  were  obtained  from 
patients in both the study and the control groups. 
First-morning urine samples were collected for the 
determination of cytokines (IL-13) and other mark-
ers. Midstream, clean-catch specimens were ob-
tained from children with adequate bladder control. 
Urine specimen bags were used for children with 
inadequate  bladder  control.  Following  collection, 
the samples were immediately centrifuged at 1000 
rpm for 10 minutes, separated from morphotic ele-
ments, frozen in 2-ml aliquots at - 80 oC, and thawed 
to room temperature immediately prior to analysis. 
Enzyme-linked immunosorbent (ELISA) 
studies
Urine CD80, CD28, and MMP-2 levels were mea-
sured using commercially available ELISA kits from 
eBioscience (San Diego, CA, USA). The minimum 
sensitivities of the CD80, CD28, and MMP-2 kits 
were 0.10, 0.18, and 3.50 ng/ml, respectively. 
Cytometric bead array (CBA) studies
The urine IL-13 and granzyme B levels were mea-
sured using commercially available CBA kits from 
Raybio (Norcross, GA, USA). The minimum sensi-
tivities limits of the IL-13 and granzyme B kits were 
0.6, and 4.0 pg/ml, respectively. 
The CBA studies were performed according to 
the relevant literature [24].
Creatinine measurements
Urine creatinine levels were measured using the 
modified Jaffe method with an automatic analyzer 
(Olympus AU 2700; Beckman Coulter, CA, USA). 
To standardize the samples and avoid dilution ef-
fects, ng/ml and pg/ml values of the urine param-
eters were divided into urine creatinine values and 
expressed as “ng/mg creatinine” and “pg/mg creati-
nine”. 
Statistical analysis
The PASW Statistics software package version 18.0 
(SPSS Inc., Chicago, IL, USA) was used for all sta-
tistical analyses. Categorical and numerical vari-
ables were expressed as frequencies and medians 
(interquartile range) because they did not show a 
normal distribution. Group comparisons were per-
formed using the Mann-Whitney U test for numeri-
cal variables and the chi-square test for categori-
cal variables. The Wilcoxon test was performed to 
test the significance of pairwise differences. Spear-
man’s  correlation  coefficient  was  calculated  for 
comparisons of active-stage urine IL-13, CD80, 
CD28, MMP-2, and granzyme B levels and between 
the active-stage IL-13, CD80, CD28, MMP-2, and 
granzyme B levels and the active stage proteinuria 
level. A p value of less than 0.05 was regarded as 
indicative of statistically significant. 
RESULTS
Demographic and biochemical characteristics
Thirty children diagnosed with MCD (age range, 
2-19 years; median, 7.2 years) and 30 healthy chil-
dren (age range, 3-16 years; median, 7.8 years) 
were included in this study. There were 12 females 
and 18 males in the study group and 14 females 
and 16 males in the control group. No statistically 
significant differences in age or sex were identified 
between the study and control groups (p=0.457 and 
p=0.602, respectively). In addition to the above age 
and sex data, the serum albumin, cholesterol, and 
creatinine levels; estimated creatinine clearance; 
and proteinuria data are provided in Table 1. The 
results were expressed as “median (minimum-max-
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As expected, the serum albumin levels of pa-
tients with active disease were significantly lower 
and the serum cholesterol and proteinuria levels 
were significantly higher than those of patients in 
remission and control subjects (p<0.001). There 
were no statistically significant differences in these 
variables between the remission phase and the 
control  group  (p>0.05).  No  statistically  significant 
differences in any other parameters were detected 
among the three groups (p>0.05) (Table 1).
Table 1. Laboratory characteristics of the children with minimal change nephrotic syndrome in the study group and 
healthy subjects in the control group
Study Group (n=30) Control Group c
(n=30)
Differences
Active stage a Remission stage b p a-c p a-b p b-c
Serum Albumin, mg/dl 1.6 (1.3-1.9) 4.3 (3.8-4.5) 4.5 (4.3-4.7) <0.001 <0.001 0.700
Serum Cholesterol, mg/dl 401 (323-485) 175 (158-192) 149 (123-171) <0.001 <0.001 0.202
Serum Creatinine, mg/dl 0.41 (0.29-0.57) 0.51 (0.40-0.59) 0.51 (0.46-0.61) 0.112 0.269 0.267
eGFR, ml/m/1.73m2 131 (115-158) 137 (115-162) 129 (114-139) 0.492 0.247 0.174
Proteinuria, mg/m2/h 93.6 (76.5-190.2) 3.2 (2.7-3.6) 2.7 (2.4-3.4) <0.001 <0.001 0.09
F: Female, M: Male, eGFR: Estimated glomerular filtration rate
IL-13 levels 
The urine IL-13 levels in the active-stage, remission, 
and control groups were 3.6 (2.1-5.7), 1.6 (1.0-2.3) 
and 1.8 (1.2-2.9) pg/mg creatinine, respectively. The 
urine IL-13 levels in the active-stage group were 
significantly higher than those in both the remission 
and control groups (p<0.001 and p=0.004, respec-
tively). There was no statistically significant differ-
ence in the urine IL-13 level between the remission 
and control groups (p=0.268). The urine IL-13 levels 
among the three groups are shown in Figure 1.
Figure 1. Urinary IL-13 levels of the study and the control 
groups
CD80 levels
The urine CD80 levels in the active-stage, remis-
sion, and control groups were 0.34 (0.18-0.53), 0.18 
(0.13-0.26) and 0.18 (0.15-0.31) ng/mg creatinine, 
respectively. The urine CD80 levels in the active-
stage were significantly higher than those in both 
the remission and control groups (p = 0.001 and p = 
0.02, respectively). There was no statistically signifi-
cant difference in the urine CD80 level between the 
remission and control groups (p = 0.807). The urine 
CD80 levels among the three groups are shown in 
Figure 2.
Figure 2. Urinary CD80 levels of the study and the control 
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CD28 levels 
The urine CD28 levels in the active-stage, remis-
sion, and control groups were 2.5 (0.5-4.9), 1.0 (0.3-
2.2) and 1.3 (0.9-1.7) ng/mg creatinine, respective-
ly. The urine CD28 levels in the active-stage were 
significantly higher than those in both the remission 
and control groups (p=0.026 and p=0.032, respec-
tively). There was no statistically significant differ-
ence in the urine CD28 level between the remission 
and control groups (p=0.659). The urine CD28 lev-
els among the three groups are shown in Figure 3.
Figure 3. Urinary CD28 levels of the study and the control 
groups
MMP-2 levels 
The urine MMP-2 levels in the active-stage, remis-
sion,  and  control  groups  were  16  (5.2-83.5),  4.2 
(1.8-11.3) and 3.2 (1.7-10.7) ng/mg creatinine, re-
spectively. The urine MMP-2 levels in the active-
stage were significantly higher than those in both 
the remission and control groups (p=0.001 and 
p=0.001, respectively). There was no statistically 
significant difference in the MMP-2 level between 
the remission and control groups (p=0.837). The 
urine MMP-2 levels among the three groups are 
shown in Figure 4.
Granzyme B levels
The urine granzyme B levels in the active-stage, 
remission, and control groups were 2.3 (1.3-6.9), 
2.1 (0.7-5.4) and 4.6 (0.9-8.6) pg/mg creatinine, re-
spectively. There were no statistically significant dif-
ferences in the granzyme B level among the three 
groups. The urine granzyme B levels among the 
three groups are shown in Figure 5.
Figure 4. Urinary MMP-2 levels of the study and the con-
trol groups
Figure 5. Urinary granzyme B levels of the study and the 
control groups
Spearman’s correlation analysis
The granzyme B level was not included in the 
Spearman correlation analysis studies because we 
did not obtain statistically significant results for this 
marker. There were no correlations among the urine 
IL-13, CD80, CD28, MMP-2, and proteinuria levels. 
A statistically significant correlation was found only 
between the urine IL-13 and CD80 levels (r=0.619, 
p<0.001). 
DISCUSSION
In this study, we gave particular attention to the fact 
that the patients had not undergone any immuno-
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time of urine collection either when the active NS 
stage or in the remission stage. This was required 
because immunosuppressive treatment inhibits cy-
tokine production. For example, CD4+ IL-13 mRNA 
expression is higher in unmedicated patients than 
in those taking steroids; in addition, steroids act to 
inhibit MMP production [25-27].
In 2004, Resier et al. evaluated the podo-
cyte CD80 molecule in rats for the first time [10]. 
Their study introduced a new perspective of the 
MCD pathogenesis. According to these research-
ers, podocyte CD80 expression changed the actin 
structure of podocyte cells, resulting in nephrotic-
level proteinuria. With respect to human studies, the 
presence of the CD80 molecule in the urine patients 
with active MCD was demonstrated by Garin et al. 
for the first time [11]. A probable reason for podocyte 
CD80 expression is rapid removal of dangerous tox-
ins and by increased glomerular permeability [28]. It 
is well known that temporary proteinuria develops in 
patients with gram-negative sepsis [29]. However, 
this proteinuria is sustained in patients with MCD. 
This is likely due to failure of CD80 inactivation be-
cause of Treg dysfunction or impaired autoregula-
tion by podocytes according to Shimada’s “two-hit” 
hypothesis [30]. Similarly, we found increased urine 
CD80 levels in patients with active-stage MCD were 
significantly higher than those in both the remission 
and control groups.
Which factor or factors induces podocyte CD80 
expression? One possibility is IL-13 [9]. IL-13 plays 
a key role in helminth infections and atopic dis-
eases [8]. Although  controversial, the association 
between MCD and atopy is generally accepted [6]. 
It has been demonstrated that human podocytes 
both express and respond to IL-4 and IL-13 [31]. 
We detected higher urine IL-13 levels in the ac-
tive stage group than in the remission and control 
groups. Moreover, there was a statistically signifi-
cant correlation between the IL-13 and CD80 levels. 
The most important study showing the relationship 
between IL-13 and MCD was performed by Lai et 
al [9]. These researchers demonstrated marked al-
buminuria, hypoalbuminemia, and hypercholester-
olemia in rats that had undergone IL-13 gene trans-
fection than in control rats. Moreover, histological 
examination of the transfected rats demonstrated 
a normal appearance by light microscopy, low IgM 
accumulation by immunofluorescence microscopy, 
foot process effacement of podocytes by electron 
microscopy, and upregulation of glomerular CD80 
gene expression, as in MCD. Therefore, we think 
that our study supports the view that IL-13 is the 
cause of a contributing factor to the high urine level 
of CD80 during the active stage of MCD. 
CD80 (B7-1) activates CD28 in humans 
(B7:CD28 pathway) [13]. Thus, T cells become acti-
vated. Another function of the B7:CD28 pathway is 
the generation of Treg cells. These cells, which are 
also known as CD4+CD25+ T cells, suppress the 
function of effector T cells [13]. Both B7 (i.e. CD80 
and CD86) and CD28 proteins are required for the 
development of these cells. Insufficiency in the de-
velopment and function of Treg cells has been ob-
served in both CD28- and B7-knockout rats [32]. 
Not numerical, functional deficiencies in Treg cells 
have been demonstrated in MCD [18]. In rat models 
of crescentic glomerulonephritis and mesangiopro-
liferative glomerulonephritis, CD28 superagonists, 
which enable increases in the number of Treg cells, 
have induced decreases in proteinuria, serum cre-
atinine levels, and crescent formation [33,34]. We 
have shown that the active-stage urine CD28 lev-
els in patients with MCD were high, along with the 
CD80 levels (i.e. the B7:CD28 pathway). This situ-
ation has led us to think that the human immune 
system  modulates  the  number  and/or  function  of 
Treg cells. 
The balance between storage and destruction 
of the extracellular matrix is critical [35]. MMPs play 
an important role in achieving this balance, MMPs 
generally destroy many extracellular matrix pro-
teins. This situation causes inflammation and fibro-
sis over time [36]. Although no inflammation is found 
in patients with MCD, it is known that proteinuria 
causes interstitial inflammation [1,37]. It has been 
shown that, MMP-2 is expressed by the podocytes 
of patients with proteinuria [38]. MMP-2 can destroy 
type-IV collagen molecules in the glomerular basal 
membrane [39, 40]. In this study, the urine MMP-2 
levels in children with active-stage MCD were higher 
than those in both the remission and control groups. 
Thus, we suggest that MMP-2 expression can be in-
duced by inflammatory effect of proteinuria and this 
situation may cause or contribute to the proteinuria 
seen in patients with MCD. 
Kaneko et al. demonstrated the absence of a 
TH1 or TH2 cytokine pattern in the pathogenesis 
of SSNS and suggested that cytotoxic T cells, NK 
cells, and/or monocytes/macrophages rather than 
TH cells may play roles in the pathogenesis using 
“three-color flow cytometry” [41]. Zeta chains on the 
surface of T and NK cells are responsible for intra-
cellular signal transmission [42]. It has been shown 
that zeta chain expression decreases in NK cells 
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nephrotic syndrome [21]. The decrease in the zeta 
chain expression indicates activation of the cell [43]. 
Therefore, this finding might be a sign of NK cell 
hyperactivity in the active stage [21]. In rat studies, 
it has been shown that granzyme/perforin-mediated 
pathways play a role in crescentic glomerulone-
phritis and that antiperforin antibodies can be used 
as  treatment  [44].  However,  we  demonstrated  in 
the present study that granzyme B activity, which 
is also a sign of NK cell hyperactivity, was neither 
low nor high in the study and control groups. In our 
opinion, it is probable that during the active stage 
of MCD, NK cell activity only remains at the level 
of decreased zeta chain expression and there is no 
need for production of granzyme B because of the 
absence of crescent formation.
In conclusion, in patients with MCD, the active-
stage urine IL-13, CD80, CD28, and MMP-2 levels 
were significantly higher than those in the remission 
and control groups. Abatacept, a fusion protein that 
blocks CD80 is used successfully in rheumatoid ar-
thritis treatment, and its use in some autoimmune 
diseases is being investigated [45-48]. Additionally, 
abatacept decreases MMP-2 levels and enhances 
Treg function [49,50]. CD28 superagonists, which 
increase the number of Treg cells, have been suc-
cessfully used in rat models of crescentic and me-
sangioproliferative  glomerulonephritis  [33,34].  In 
adults, lebrikizumab, an anti-IL-13 antibody, is suc-
cessfully used in asthma treatment [51]. Treatment 
of anti-Thy2.2. nephritis, which is a rat model of me-
sangioproliferative glomerulonephritis (equivalent to 
Ig A nephropathy in humans), with the MMP-2 inhib-
itor BB-1101 decreases the extracellular matrix stor-
age, glomerular hypertrophy, and proteinuria [52]. 
It is probable that in the future anti-CD80 and anti-
IL-13 antibodies, CD28 superagonists, and MMP 
inhibitors will either replace or be used as adjuncts 
to the long-used immunosuppressive treatments for 
steroid-resistant MCD. Therefore, we suggest that 
the roles of these treatment modalities in steroid 
and other immunsuppressive-resistant MCD should 
be investigated.
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